Canergy 100 mg Tablets for Dogs

Authorised

- Propentofylline

Product identification

Medicine name:
Canergy 100 mg Tablets for Dogs
Canergy vet. 100 mg töflur fyrir hunda

Active substance:
Propentofylline

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Propentofylline
100.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Tablet

Withdrawal period by route of administration:
Oral use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QC04AD90

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Iceland

Package description:
Cardboard box with 7 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 6 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 50 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 5 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 4 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 3 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 25 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 2 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 10 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 1 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 9 Aluminium - PA_ALU_PVC blister of 10 tablets
Cardboard box with 8 Aluminium - PA_ALU_PVC blister of 10 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 13(1) of Directive No 2001/82/EC)

Marketing authorisation holder:

Le Vet. Beheer B.V.

Marketing authorisation date:
11/05/2015

Manufacturing sites for batch release:
Artesan Pharma GmbH & Co. KG
Lelypharma B.V.
Genera d.d.

Responsible authority:
Icelandic Medicines Agency

Authorisation number:
IS/2/15/006/01

Date of authorisation status change:
4/05/2020

Reference member state:
Netherlands

Procedure number:
NL/V/0313/001

Concerned member states:
Austria Belgium Croatia Cyprus Czechia Denmark Estonia Finland France Germany Greece Hungary Iceland Ireland Italy Latvia Lithuania Luxembourg Norway Poland Portugal Romania Slovakia Slovenia Spain Sweden United Kingdom (Northern Ireland)

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

---